Sellas Life Sciences Group Inc Stock Price, News & Analysis

SELLAS Life Sciences Group (NASDAQ: SLS) reported encouraging results from its Phase 1/2 clinical trial of its lead immunotherapy, galinpepimut-S (GPS), combined with pembrolizumab for advanced ovarian cancer. Notably, 100% of patients are alive, and 45.5% continue with the treatment. CD8+ T-cell responses increased by an average of +242%, indicating robust immune activation. The disease control rate was 63.6%, with a median progression-free survival of 11.8 weeks in a challenging patient cohort. These findings suggest potential for GPS as a viable therapy in difficult-to-treat cases.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced promising results from a Phase 1 trial combining its lead candidate, galinpepimut-S (GPS), with nivolumab for treating malignant pleural mesothelioma (MPM). Patients showed a median overall survival of 35.4 weeks, compared to approximately 28 weeks with standard care. The combination therapy appears to provide significant clinical benefits, especially for patients who have failed traditional treatments. SELLAS plans to provide further clinical data by the end of Q4 2021.

SELLAS Life Sciences Group (Nasdaq: SLS) announced its inclusion in the Russell Microcap Index, effective June 28, 2021. This inclusion is a significant milestone expected to enhance the company's visibility within the investment community. SELLAS, known for developing cancer immunotherapies, notably its lead candidate GPS, aims to provide treatment options for various cancer types. The Russell Microcap Index inclusion lasts for a year and is determined by market capitalization and style attributes, impacting approximately $10.6 trillion in assets.

SELLAS Life Sciences Group announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering galinpepimut-S (GPS) in combination with checkpoint inhibitors for treating WT1-expressing cancers. This patent extends to at least 2036 and facilitates further clinical studies for patients with advanced ovarian cancer and malignant pleural mesothelioma. CEO Angelos Stergiou emphasized the importance of this milestone for advancing their clinical pipeline and intends to release more data later this quarter.

SELLAS Life Sciences Group (SLS) announced a milestone payment of $1.0 million from 3D Medicines under an exclusive license for Galinpepimut-S (GPS) in Greater China. The company recognized $5.7 million in licensing revenue for Q1 2021 and received approval for the Phase 3 REGAL study in Greece, with patient enrollment planned in France and Germany by Q2. R&D expenses rose to $4.3 million due to increased clinical preparations, while general and administrative expenses reached $3.6 million. The net loss narrowed to $2.4 million, with cash reserves at approximately $28 million.

SELLAS Life Sciences Group (Nasdaq: SLS) will hold a Shareholder Update Call on June 3, 2021, at 8:30 a.m. ET, hosted by President & CEO Angelos Stergiou. The call will provide a corporate update on the company’s progress and future plans in developing cancer immunotherapies.

Participants can join via toll-free numbers or online, with a replay available until June 17, 2021. The company's lead product candidate, galinpepimut-S (GPS), targets the WT1 protein for various cancers, while nelipepimut-S (NPS) aims to treat early-stage HER2+ breast cancer.

SELLAS Life Sciences Group (SLS) has signed an exclusive license agreement with 3D Medicines for the development and commercialization of Galinpepimut-S (GPS) in China, receiving a $7.5 million upfront fee and potential total payments of $202 million. As of December 31, 2020, SELLAS reported cash and equivalents of $35.3 million, a significant increase from prior periods. The ongoing Phase 3 REGAL study in Acute Myeloid Leukemia has expanded to approximately 135 clinical sites. Additionally, preliminary clinical data show promising results for GPS in combination with therapies for ovarian cancer and mesothelioma.

SELLAS Life Sciences Group (Nasdaq: SLS) announced that its CEO, Angelos Stergiou, will participate in the Emerging Growth Virtual Conference on March 17, 2021. He will discuss developments in cancer immunotherapies and participate in a Cancer Vaccines Panel at 1:00 p.m. ET. The focus will be on market opportunities and milestones for cancer vaccines. An archived replay will be available on SELLAS' investor relations website. Additionally, SELLAS is advancing its lead product candidate, galinpepimut-S, targeting the WT1 protein across various cancers.

SELLAS Life Sciences Group has initiated its pivotal Phase 3 REGAL study of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients across the U.S. and Europe. In partnership with 3D Medicines, it has begun commercialization of GPS in China, backed by a $35.3 million cash reserve as of December 31, 2020. Preliminary results from its Phase 2 study indicate a median overall survival of 21 months for GPS-treated AML patients. The company's strong financial position will support ongoing clinical programs and potential future royalties from the 3D Medicines agreement may reach $202 million.